<DOC>
	<DOCNO>NCT02614196</DOCNO>
	<brief_summary>The main purpose study evaluate efficacy study drug know LY2951742 participant episodic migraine .</brief_summary>
	<brief_title>Evaluation LY2951742 Prevention Episodic Migraine- EVOLVE-2 Study</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Have diagnosis episodic migraine define International Headache Society ( IHS ) International Classification Headache Disorders ( ICHD ) 3 beta guideline ( 1.1 1.2 ) ( ICHD3 2013 ) , history migraine headache least 1 year prior screening , migraine onset prior age 50 . Are currently enrol participate within last 30 day within 5 halflives ( whichever longer ) clinical trial involve investigational product . Current use prior exposure LY2951742 another CGRP antibody . Known hypersensitivity multiple drug , monoclonal antibody therapeutic protein , LY2951742 . History persistent daily headache , cluster headache migraine subtypes include hemiplegic ( sporadic familial ) migraine , ophthalmoplegic migraine , migraine brainstem aura ( basilartype migraine ) define IHS ICHD3 beta .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>prevention</keyword>
	<keyword>prophylaxis</keyword>
	<keyword>headache</keyword>
</DOC>